GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silexion Therapeutics Corp (NAS:SLXN) » Definitions » DeferredTaxAndRevenue

SLXN (Silexion Therapeutics) DeferredTaxAndRevenue : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Silexion Therapeutics DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Silexion Therapeutics's current deferred tax and revenue for the quarter that ended in Sep. 2024 was $0.00 Mil.

Silexion Therapeutics DeferredTaxAndRevenue Historical Data

The historical data trend for Silexion Therapeutics's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silexion Therapeutics DeferredTaxAndRevenue Chart

Silexion Therapeutics Annual Data
Trend Dec22 Dec23
DeferredTaxAndRevenue
- -

Silexion Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
DeferredTaxAndRevenue Get a 7-Day Free Trial - - - - -

Silexion Therapeutics DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Silexion Therapeutics's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Silexion Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
2 Ha mayan Street, Modi in-Maccabim-Reut, ISR, 7177871
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.